Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EA Pharma, Mochida in Tie-Up Deal for 2nd Constipation Med
October 4, 2017
- Torii Named CEO of Fujifilm-Kyowa Kirin JV after Humira Biosimilar Filing
October 4, 2017
- JT and Bayer Begin Japan PIII for HIF-PH Inhibitors, Follow Astellas and GSK
October 4, 2017
- Celgene Looks to Expand Footprint in Japan Unmet Need Arena
October 4, 2017
- Japan Debut of MSD’s Zetia/Lipitor Combo Delayed as Cyberattack Woes Continue
October 4, 2017
- Shoichiro Ogawa Tapped as Alcon Pharma Japan Chief
October 3, 2017
- Olaparib Gets Orphan Status for BRCA-Mutated Breast Cancer
October 3, 2017
- Astellas to Launch 3-Way Copromotion Scheme for Kiklin
October 3, 2017
- Yoshindo Licenses Nesp Biosimilar from South Korea’s CJ Healthcare
October 3, 2017
- AZ Contesting Employee Lawsuits; First Oral Arguments Held at Tokyo District Court
October 3, 2017
- JCR Files Fabrazyme Biosimilar for Japan Approval
October 3, 2017
- SI-613 Enters PIIb Study for Enthesopathy: Ono, Seikagaku
October 3, 2017
- Takeda Links with Swedish, Canadian Organizations on IBD Research
October 2, 2017
- Opdivo-Yervoy Combo Filed in Japan for Melanoma
October 2, 2017
- Alexandre de Muralt to Lead Merck Serono Japan
September 29, 2017
- Novartis Japan Chief Sees CAR-T Pricing as “Important Issue” Here Too
September 29, 2017
- VLP Flu Vaccine Enters PIII in North America, Europe: Mitsubishi Tanabe
September 28, 2017
- Sumitomo Dainippon to Slash Manufacturing Jobs via Another Voluntary Redundancy Program
September 28, 2017
- Nichi-Iko Earns Remicade Biosimilar Nod, Picks GI-Savvy Zeria as Copromotion Ally
September 28, 2017
- Japan Approves 1st Rituxan Biosimilar from Sandoz
September 28, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…